Teva Pharmaceutical Industries (NYSE:TEVA) Now Covered by Analysts at Guggenheim
Guggenheim initiated coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a report published on Thursday, BenzingaRatingsTable reports. The brokerage issued a neutral rating on the stock.
Other equities research analysts also recently issued reports about the stock. Barclays started coverage on shares of Teva Pharmaceutical Industries in a report on Tuesday, June 11th. They issued an underweight rating and a $8.00 price target for the company. Argus raised shares of Teva Pharmaceutical Industries from a hold rating to a buy rating and set a $12.00 price target for the company in a report on Friday, July 5th. Morgan Stanley downgraded shares of Teva Pharmaceutical Industries from an equal weight rating to an underweight rating and cut their price target for the company from $16.00 to $6.00 in a report on Monday, July 15th. Wells Fargo & Co set a $17.00 price target on shares of Teva Pharmaceutical Industries and gave the company a hold rating in a report on Tuesday, May 28th. Finally, CIBC raised shares of Teva Pharmaceutical Industries from a market perform rating to an outperform rating and set a $12.00 price target for the company in a report on Monday, June 3rd. Six investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of Hold and an average price target of $12.80.
NYSE TEVA traded down $0.23 on Thursday, reaching $7.95. The company’s stock had a trading volume of 554,715 shares, compared to its average volume of 22,780,964. Teva Pharmaceutical Industries has a twelve month low of $6.07 and a twelve month high of $25.13. The company has a debt-to-equity ratio of 1.73, a quick ratio of 0.62 and a current ratio of 0.96. The stock has a market cap of $8.88 billion, a PE ratio of 2.84, a PEG ratio of 0.85 and a beta of 1.68. The firm’s 50 day moving average is $7.21 and its two-hundred day moving average is $11.25.
A number of hedge funds have recently bought and sold shares of TEVA. First Interstate Bank purchased a new stake in Teva Pharmaceutical Industries during the second quarter valued at about $28,000. Pacer Advisors Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $32,000. Kavar Capital Partners LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $35,000. G&S Capital LLC increased its holdings in shares of Teva Pharmaceutical Industries by 99.4% in the 2nd quarter. G&S Capital LLC now owns 4,012 shares of the company’s stock valued at $37,000 after purchasing an additional 2,000 shares during the period. Finally, NEXT Financial Group Inc increased its holdings in shares of Teva Pharmaceutical Industries by 384.8% in the 2nd quarter. NEXT Financial Group Inc now owns 4,276 shares of the company’s stock valued at $39,000 after purchasing an additional 3,394 shares during the period. 57.85% of the stock is owned by institutional investors.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Story: Stock Selection – What is cash flow?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.